Assessing Ascendis Pharma (NasdaqGS:ASND) Valuation After Recent Share Price Weakness

Recent share performance and business snapshot

Ascendis Pharma (NasdaqGS:ASND) stock has been under pressure recently, with the share price down about 4% over the past week and about 12% over the past month, closing at US$210.45.

The company, a Denmark based biopharmaceutical group with a market value near US$13.1b, focuses on TransCon based therapies such as SKYTROFA and YORVIPATH, alongside additional endocrinology and oncology candidates in clinical development.

See our latest analysis for Ascendis Pharma.

That recent weakness continues a softer trend, with the year to date share price return down 14.24%. Momentum has been fading even as Ascendis Pharma advances its TransCon endocrinology and oncology portfolio.

If Ascendis Pharma’s recent pullback has you reassessing your watchlist, it could be a good time to broaden your search and check out 38 healthcare AI stocks

With Ascendis Pharma trading at US$210.45, a value score of 4, and an estimated intrinsic discount of about 67%, you have to ask: is this a genuine opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 38.5% Undervalued

Ascendis Pharma’s most followed narrative points to a fair value of about $342.08 per share, well above the recent close at $210.45, framing the stock as materially undervalued in that lens.

Partnerships such as the collaboration with Novo Nordisk on once monthly TransCon semaglutide and ex U.S. partners like Teijin for endocrine products extend the TransCon model into larger disease areas and additional geographies. This can add new royalty or collaboration streams alongside product sales and support earnings as R&D productivity improves.

Read the complete narrative.

Want to see what sits underneath that valuation gap? The narrative leans on fast compounding revenue, a steep margin shift, and a future earnings multiple more often linked to mature growth leaders.

Result: Fair Value of $342.08 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this hinges on YORVIPATH and TransCon CNP meeting high expectations, while heavy global commercial spending could limit the earnings progress implied in the narrative.

Find out about the key risks to this Ascendis Pharma narrative.

Next Steps

With sentiment split between opportunity and concern, this is a moment to look at the data yourself and decide where you stand, starting with the 4 key rewards and 2 important warning signs

Looking for more investment ideas?

If Ascendis Pharma is on your radar, do not stop there. Broaden your research now or you risk missing other opportunities that might fit even better.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com